DuPont Reports Second Quarter 2026 Results

DuPont de Nemours, Inc. (DD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DuPont Reports Second Quarter 2026 Results Exceeds Second Quarter 2026 Guidance Raises Full Year 2026 Guidance Second Quarter 2026 Highlights • Net Sales of $1.8 billion increased 4%; organic sales increased 4% versus year-ago period • GAAP Income from continuing ope

Event · Earnings
Also in this documentGuidance · raise · $7.16K–$7.19KBuyback · $250M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 4, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DD
Bullish
high confidence
Mentioned
$DD
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DDBullishHigh
01

Why it matters

The company reported 2Q26 net sales of $1.819B (+4% YoY), transaction-adjusted free cash flow of $326M (127% conversion), and raised full-year 2026 guidance for operating EBITDA and adjusted EPS, while also announcing intent to repurchase $250M of shares in Q3.

02

Market read

This is a primary earnings-and-guidance update with explicit full-year ranges and a buyback intent, which can drive estimate revisions and near-term positioning.

03

What to watch

The filing highlights margin pressure drivers (mix and growth investments) and a large GAAP swing from prior-year items, so traders should watch for whether adjusted metrics are sustained rather than one-off improvements.

Relevance 9/10Novelty 9/10Timing: pre-market today, guidance raise and buyback intent disclosed in an 8-K
AlphAI · Earnings readDD · Second Quarter 2026 · ended June 30, 2026

DuPont Reports Second Quarter 2026 Results Exceeds Second Quarter 2026 Guidance Raises Full Year 2026 Guidance

✓Strong quarter

Net sales and organic sales each increased 4%, operating EBITDA increased 6%, adjusted EPS increased 48%, and transaction-adjusted free cash flow increased 205%. The company also raised full-year 2026 guidance.

Revenue
$1.82B
4% y/y
Healthcare & Water Technologies
$856M
5% y/y
EPS · non-GAAP
$1.88
48% y/y
2H'26E and Full Year 2026E outlook
2H'26E: $3,660 - $3,690; Full Year 2026E: $7,160 - $7,190

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$1.82B–4%
Organic salesnon-GAAP4%–4%
GAAP Income from continuing operationsGAAP$191M–n.m.
Operating EBITDAnon-GAAP$448M–6%
Operating EBITDA marginnon-GAAP24.6%–40 bps
GAAP EPS from continuing operationsGAAP$1.37–n.m.
Adjusted EPSnon-GAAP$1.88–48%
Cash provided by operating activities from continuing operationsGAAP$400M–n.m.
Capital expendituresother$76M––
Separation-related transaction costs and other paymentsother$2M––
Transaction-adjusted free cash flownon-GAAP$326M–205%
Transaction-adjusted free cash flow conversionnon-GAAP127%––
Healthcare & Water Technologies Operating EBITDAnon-GAAP$258M–4%
Healthcare & Water Technologies Operating EBITDA marginnon-GAAP30.1%–(30) bps
Diversified Industrials Operating EBITDAnon-GAAP$213M–7%
Diversified Industrials Operating EBITDA marginnon-GAAP22.1%–70 bps

Segments

SegmentRevenueq/qy/y
Healthcare & Water TechnologiesNet sales increased on organic sales growth of 4% and a currency benefit of 1%. Healthcare Technologies sales were up mid-single digits on an organic basis on broad-based growth led by personal protection and biopharma. Water Technologies sales were up low-single digits on an organic basis on continued strength in industrial water and semiconductor markets, partially offset by weakness in the Middle East.$856M–5%
Diversified IndustrialsNet sales increased on organic sales growth in the quarter. Building Technologies sales were up low-single digits on an organic basis due to growth in residential and non-residential construction markets. Industrial Technologies sales were up mid-single digits on an organic basis on continued strength in aerospace coupled with growth in electric vehicle applications.$963M–3%

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

2H'26E and Full Year 2026E outlook

  • Revenue2H'26E: $3,660 - $3,690; Full Year 2026E: $7,160 - $7,190
  • NoteOperating EBITDA: 2H'26E: $890 - $910; Full Year 2026E: $1,750 - $1,770
  • NoteAdjusted EPS: 2H'26E: $3.65 - $3.80; Full Year 2026E: $7.17 - $7.32
  • NoteFull-year 2026 operating EBITDA guidance midpoint: approximately $1.76 billion
  • NoteAdjusted EPS guidance midpoint: $7.24 per share
  • NoteExpectation for organic sales growth: slightly above 4%
  • NoteSecond-half organic sales growth expectation: mid-single digit organic sales growth

Capital returns

  • Announces intent to repurchase $250 million of shares in the third quarter.

What drove it

  • Consolidated operating EBITDA increased on organic growth and productivity.
  • GAAP Income and GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.
  • Adjusted EPS increased on higher segment earnings, lower net interest expense and a lower tax rate.
  • Healthcare & Water Technologies operating EBITDA increased on organic growth and productivity, partially offset by growth investments.
  • Diversified Industrials operating EBITDA and margin increased on organic growth, favorable mix and productivity.
  • The company cited continued strength across healthcare, industrial water, and aerospace end-markets.

Concerns

  • Healthcare & Water Technologies operating EBITDA margin decreased 30 basis points as organic growth and productivity were more than offset by less favorable mix and growth investments.
  • Water Technologies strength in industrial water and semiconductor markets was partially offset by weakness in the Middle East.
  • The filing identifies risks and costs related to the arrangement to share future eligible PFAS costs among DuPont, Corteva, Inc. and The Chemours Company.
  • The financial results of the divested Aramids Business and the Electronics Business are reflected as discontinued operations.

What to watch

  • Delivery of 2H'26E net sales of $3,660 - $3,690, operating EBITDA of $890 - $910 and adjusted EPS of $3.65 - $3.80.
  • Whether organic sales growth reaches the expectation of slightly above 4% for full-year 2026 and mid-single digit growth in the second half.
  • Margin progression in Healthcare & Water Technologies following the 30 basis point decline.
  • Continued strength in healthcare, industrial water, aerospace, construction and electric vehicle applications.
  • Execution of the intent to repurchase $250 million of shares in the third quarter.

Balance sheet and cash flow

  • Cash provided by operating activities from continuing operations was $400 million.
  • Capital expenditures were $76 million.
  • Separation-related transaction costs and other payments were $2 million.
  • Transaction-adjusted free cash flow was $326 million, representing 127% conversion.
  • The Aramids Divestiture was completed on April 1, 2026 for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable in the principal amount of $300 million and a non-controlling common equity interest valued at $325 million.

Analysis

DuPont reported a strong second quarter ended June 30, 2026. Net sales were $1,819 million, up 4%, with organic sales also up 4%. Operating EBITDA increased 6% to $448 million and operating EBITDA margin increased 40 bps to 24.6%. GAAP Income from continuing operations was $191 million, compared with $24 million, while GAAP EPS from continuing operations was $1.37, compared with $0.17.

Growth was present in both reporting segments. Healthcare & Water Technologies generated net sales of $856 million, up 5%, including 4% organic growth and a 1% currency benefit. Healthcare Technologies benefited from personal protection and biopharma, while Water Technologies saw continued strength in industrial water and semiconductor markets. Diversified Industrials generated net sales of $963 million, up 3%, supported by construction-market growth, continued aerospace strength and growth in electric vehicle applications.

Profitability was led by productivity and mix in Diversified Industrials, where operating EBITDA increased 7% to $213 million and margin increased 70 bps to 22.1%. Healthcare & Water Technologies operating EBITDA increased 4% to $258 million, but margin declined 30 basis points to 30.1% because less favorable mix and growth investments more than offset organic growth and productivity. At the consolidated level, adjusted EPS increased 48% to $1.88, with higher segment earnings, lower net interest expense and a lower tax rate cited as drivers.

Cash generation strengthened materially. Cash provided by operating activities from continuing operations was $400 million, capital expenditures were $76 million and separation-related transaction costs and other payments were $2 million. These items resulted in transaction-adjusted free cash flow of $326 million and 127% conversion. The company announced its intent to repurchase $250 million of shares in the third quarter.

Management raised full-year 2026 guidance to net sales of $7,160 - $7,190, operating EBITDA of $1,750 - $1,770 and adjusted EPS of $7.17 - $7.32. The stated full-year midpoint targets are approximately $1.76 billion of operating EBITDA and $7.24 per share of adjusted EPS, with organic sales growth expected to be slightly above 4%. The second-half outlook calls for net sales of $3,660 - $3,690, operating EBITDA of $890 - $910, adjusted EPS of $3.65 - $3.80 and mid-single digit organic sales growth.

Management, verbatim

We delivered another strong quarter, exceeding our financial guidance and demonstrating our focus on consistent execution

Lori Koch, DuPont Chief Executive Officer

Mid-single digit organic growth, strong margin expansion, coupled with robust adjusted EPS growth and free cash flow generation underscore the strength of our market-leading businesses and reflect disciplined execution of our strategic priorities, supported by our ongoing focus on excellence and productivity.

Lori Koch, DuPont Chief Executive Officer

Our strong execution and market-driven growth continue to translate into higher earnings and free cash flow generation. As a result of our second quarter outperformance, we are again raising the midpoint of our full-year 2026 operating EBITDA guidance to approximately $1.76 billion and adjusted EPS guidance to $7.24 per share, while increasing our expectation for organic sales growth to slightly above 4%.

Antonella Franzen, DuPont Chief Financial Officer

Not in the filing

stated, not guessed
  • Prior-quarter values and quarter-over-quarter comparisons for reported metrics.
  • Gross profit and gross margin.
  • GAAP operating income and GAAP operating margin.
  • Total net income, net income attributable to common stockholders and diluted share count.
  • Cash balance, debt balance and other period-end balance-sheet metrics.
  • Dividend declaration or payment details.
  • Completed share repurchases during the reported quarter.
  • Full-year 2026 guidance for gross margin, operating expenses, tax rate, operating cash flow, free cash flow and capital expenditures.
  • Prior outlook figures, which were not provided, for comparison with reported results.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

DuPont filed an SEC 8-K (Item 2.02) with its 2Q26 results and updated 2026 outlook.

Company-level read

Ticker impact

$DDBullishHigh confidence
Context

DuPont reported 2Q26 results and raised full-year 2026 guidance, including adjusted EPS to $7.24 midpoint and operating EBITDA to about $1.76B.

Expected impact

Likely upward bias for DD as traders reprice 2026 earnings and free-cash-flow expectations; follow-through depends on whether organic growth sustains in 2H.

Evidence & confidence

The filing is a primary disclosure (8-K) with specific, updated full-year ranges and a concrete repurchase authorization, which typically drives immediate sentiment and estimate revisions.

Market effects

Supports the industrials/chemicals narrative that mid-single-digit organic growth and margin expansion are achievable, potentially improving sentiment for peers with similar end-market exposure.

Primarily US-listed large-cap industrials sentiment; limited direct regional spillover beyond US earnings/guidance tape.

Global end-market strength signals (healthcare, industrial water, aerospace) may modestly influence multinational industrials positioning.

Counterpoint

Guidance raises may already be partially anticipated; investors may focus on whether 2H organic growth can remain slightly above 4% amid mix and investment headwinds.

Key entities

  • DuPont de Nemours, Inc.

    Reported 2Q26 results, raised full-year 2026 guidance, and announced $250M share repurchase intent.

  • Lori Koch

    CEO quoted on execution and guidance outperformance.

  • Antonella Franzen

    CFO quoted on raising guidance and 2H growth expectations.

Every DD earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$DDMed

Wells Fargo raises DuPont stock price target to $170 on valuation

Wells Fargo raised its price target for DuPont (NYSE:DD) to $170 from $166, maintaining an Overweight rating. The firm cites a higher-quality portfolio and a 2027 EV/EBITDA multiple of 13x. DuPont reported Q3 earnings of $2.09 per share on $1.9B revenue, a 4% increase. UBS also raised its target to $182, citing margin strength. Shares trade at $150.73, with potential upside to $170.

$DDHighAI 9/10

What Just Happened To DuPont Stock?

DuPont (DD) stock rose 8.6% on November 3, 2026, after reporting Q3 2026 earnings of $2.09 per share, beating estimates of $1.87. Sales reached $1.9B, up 4% YoY. The company raised its full-year guidance to $7.50 EPS and $7.19B in sales. Management cited strong order growth but delayed some Middle East projects to 2027. Most peers fell, with only Celanese rising 5.0%.

$DDHighAI 9/10

DuPont de Nemours Q3 Earnings Call Highlights

DuPont (NYSE: DD) reported Q3 Diversified Industrials operating EBITDA up 11% to $242M, with a 24.1% margin. The company highlighted productivity gains, AI initiatives, and raised its 2026 outlook to $7.19B in net sales and $1.785B in EBITDA. Q4 projections include $1.825B in net sales and $455M in EBITDA. DuPont also announced share repurchases and M&A plans.